Advisors Asset Management, Inc. - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.

Quarter-by-quarter ownership
Advisors Asset Management, Inc. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2020$160,000
-62.2%
3,848
-56.4%
0.00%
-62.5%
Q2 2020$423,000
-24.7%
8,831
-1.0%
0.01%
-38.5%
Q1 2020$562,000
-51.3%
8,923
-4.1%
0.01%
-35.0%
Q4 2019$1,153,000
+10.0%
9,306
-41.1%
0.02%
+5.3%
Q3 2019$1,048,000
-18.9%
15,799
-2.7%
0.02%
-17.4%
Q2 2019$1,292,000
-30.6%
16,240
-2.5%
0.02%
-30.3%
Q1 2019$1,863,000
+29.7%
16,653
+16.9%
0.03%
+13.8%
Q4 2018$1,436,000
+69.7%
14,243
+112.7%
0.03%
+107.1%
Q3 2018$846,000
+1410.7%
6,696
+1197.7%
0.01%
+1300.0%
Q4 2016$56,000
-42.3%
516
-12.7%
0.00%
-50.0%
Q3 2016$97,000
+14.1%
591
-1.0%
0.00%
+100.0%
Q2 2016$85,000
+6.2%
597
-4.2%
0.00%0.0%
Q1 2016$80,000
-12.1%
623
+2.5%
0.00%0.0%
Q4 2015$91,000
-77.9%
608
-75.5%
0.00%
-85.7%
Q3 2015$411,000
+110.8%
2,481
+206.7%
0.01%
+133.3%
Q2 2015$195,000
-21.1%
809
-7.5%
0.00%0.0%
Q1 2015$247,000
+79.0%
875
-0.9%
0.00%
+50.0%
Q4 2014$138,000
-32.7%
883
+2.1%
0.00%
-33.3%
Q3 2014$205,000
+12.0%
865
+11.8%
0.00%0.0%
Q2 2014$183,000
+346.3%
774
+524.2%
0.00%
+200.0%
Q1 2014$41,0001240.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2016
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders